Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

Autor: Lang, Jennifer, Vincent, Ludwig, Chenel, Marylore, Ogungbenro, Kayode, Galetin, Aleksandra

Publikováno v: In European Journal of Pharmaceutical Sciences 1 October 2021 165

Impact of hepatic CYP3A4 ontogeny functions on DDI risk in paediatric PBPK/PD modelling: critical literature review and ivabradine case study

Autor: Lang, Jennifer, Vincent, Ludwig, Chenel, Marylore, Ogungbenro, Kayode, Galetin, Aleksandra

Publikováno v: Lang, J, Vincent, L, Chenel, M, Ogungbenro, K & Galetin, A 2020, ' Impact of hepatic CYP3A4 ontogeny functions on DDI risk in paediatric PBPK/PD modelling: critical literature review and ivabradine case study ', Clinical Pharmacology & Therapeutics, vol. 0, 0, pp. 0 . https://doi.org/10.1002/cpt.2134

Clinical assessment of drug-drug interaction (DDI) in children is not a common practice in drug development. Therefore, physiologically-based-pharmacokinetic (PBPK) modelling can be beneficial for informing drug labelling. Using ivabradine and its me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::aea787977de142265198920611631291
https://www.research.manchester.ac.uk/portal/en/publications/impact-of-hepatic-cyp3a4-ontogeny-functions-on-ddi-risk-in-paediatric-pbpkpd-modelling-critical-literature-review-and-ivabradine-case-study(0793b48c-e6f9-4be3-873a-baf0f1658891).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Molecular and cellular pharmacological properties of 5-methoxycarbonylamino- N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand.

Autor: Vincent, Ludwig¹, Cohen, William¹, Delagrange, Philippe², Boutin, Jean A.¹ jean.boutin@fr.netgrs.com, Nosjean, Olivier¹

Publikováno v: Journal of Pineal Research. Apr2010, Vol. 48 Issue 3, p222-229. 8p. 2 Charts, 5 Graphs.

Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.

Autor: Parmentier, Yannick, Pothier, Corinne, Hewitt, Nicola, Vincent, Ludwig, Caradec, Fabrice, Liu, Jia, Lin, Feifei, Trancart, Marie-Michèle, Guillet, Fabrice, Bouaita, Belkacem, Chesne, Christophe, Walther, Bernard

Publikováno v: Xenobiotica; Jan2019, Vol. 49 Issue 1, p22-35, 14p